Ardana plc (LSE:ARA) the emerging pharmaceutical company focused on improving human reproductive health, today announces that it has signed an agreement under which Ardana grants Pharmacuro ApS exclusive rights to market Striant™SR, Ardana’s testosterone replacement therapy for male hypogonadism, in the Nordic region.
